Phase III

Darts failing to hit bullseye
Pharma

EyePoint phase 3 for AMD disappoints, tanking stock

EyePoint turned to an ad hoc analysis in an effort to salvage the tyrosine kinase inhibitor’s performance in a phase 3 trial.
Donavyn Coffey Aug 17, 2026 3:30pm
Merck Co

Merck's Keytruda chalks up stomach cancer trial win

Nov 22, 2022 11:00am